These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28983562)

  • 1. Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen.
    Goldstein DA
    JAMA Oncol; 2017 Dec; 3(12):1628-1629. PubMed ID: 28983562
    [No Abstract]   [Full Text] [Related]  

  • 2. Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.
    Retèl VP; Steuten LMG; Geukes Foppen MH; Mewes JC; Lindenberg MA; Haanen JBAG; van Harten WH
    BMC Cancer; 2018 Sep; 18(1):895. PubMed ID: 30219040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
    Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
    BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
    Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
    Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting.
    Guglieri-López B; Pérez-Pitarch A; Porta Oltra B; Ferriols-Lisart F; Royo-Peiró Á; Climente-Martí M
    Anticancer Drugs; 2016 Aug; 27(7):679-84. PubMed ID: 27058705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings.
    Jarkowski A; Nestico JS; Vona KL; Khushalani NI
    J Oncol Pharm Pract; 2014 Feb; 20(1):47-50. PubMed ID: 23512270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL.
    Russi A; Chiarion-Sileni V; Damuzzo V; Di Sarra F; Pigozzo J; Palozzo AC
    Int J Technol Assess Health Care; 2017 Jan; 33(2):199-205. PubMed ID: 28703084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
    Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
    J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
    Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
    Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
    Spain L; Larkin J
    Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal.
    Miguel LS; Lopes FV; Pinheiro B; Wang J; Xu R; Pellissier J; Laires PA
    Value Health; 2017 Sep; 20(8):1065-1073. PubMed ID: 28964438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accounting for Cured Patients in Cost-Effectiveness Analysis.
    Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
    Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
    Pike E; Hamidi V; Saeterdal I; Odgaard-Jensen J; Klemp M
    BMJ Open; 2017 Aug; 7(8):e014880. PubMed ID: 28827234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
    McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
    Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "value" of immune-checkpoint inhibitors for advanced lung cancer.
    Inoue A
    Respir Investig; 2017 Jul; 55(4):253-254. PubMed ID: 28705302
    [No Abstract]   [Full Text] [Related]  

  • 16. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.
    Chan PY; Hall P; Hay G; Cohen VML; Szlosarek PW
    Pigment Cell Melanoma Res; 2017 Jan; 30(6):558-562. PubMed ID: 28640512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost of ipilimumab toxicity: a single-centre analysis.
    Yousaf N; Davidson M; Goode E; Thomas C; Hung R; Gore M; Larkin J
    Melanoma Res; 2015 Jun; 25(3):259-64. PubMed ID: 25860328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
    Letendre P; Monga V; Milhem M; Zakharia Y
    Future Oncol; 2017 Mar; 13(7):625-636. PubMed ID: 27882779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab-Based
 Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events With Ipilimumab Monotherapy and Combination Therapy With Nivolumab.
    Madden KM; Hoffner B
    Clin J Oncol Nurs; 2017 Aug; 21(4 Suppl):30-41. PubMed ID: 28738054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.